Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.
Vrieling C, Assele SY, Moser L, Sauvé N, Litière S, Fourquet A, Poortmans P, Struikmans H, van Tienhoven G, Bartelink H, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups. Vrieling C, et al. Eur J Cancer. 2021 Sep;155:28-37. doi: 10.1016/j.ejca.2021.06.018. Epub 2021 Jul 29. Eur J Cancer. 2021. PMID: 34333446
Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
Vrieling C, Collette L, Bartelink E, Borger JH, Brenninkmeyer SJ, Horiot JC, Pierart M, Poortmans PM, Struikmans H, Van der Schueren E, Van Dongen JA, Van Limbergen E, Bartelink H. Vrieling C, et al. Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):667-76. doi: 10.1016/s0360-3016(99)00215-1. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524421 Clinical Trial.
The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Van der Hulst M, Van der Schueren E, Bartelink H. Vrieling C, et al. Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):677-85. doi: 10.1016/s0360-3016(99)00211-4. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524422 Clinical Trial.
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Maat B, Van Limbergen E, Bartelink H. Vrieling C, et al. Radiother Oncol. 2000 Jun;55(3):219-32. doi: 10.1016/s0167-8140(00)00210-3. Radiother Oncol. 2000. PMID: 10869738 Clinical Trial.
Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM, Struikmans H, Van den Bogaert W, Bartelink H; EORTC Radiotherapy, Breast Cancer Groups. Vrieling C, et al. Eur J Cancer. 2003 May;39(7):932-44. doi: 10.1016/s0959-8049(03)00123-0. Eur J Cancer. 2003. PMID: 12706362 Clinical Trial.
Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, Schinagl D, Oei B, Rodenhuis CC, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan DA, Dubois JB, Remouchamps V, Mirimanoff RO, Hart G, Collette S, Collette L, Bartelink H; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups. Vrieling C, et al. JAMA Oncol. 2017 Jan 1;3(1):42-48. doi: 10.1001/jamaoncol.2016.3031. JAMA Oncol. 2017. PMID: 27607734 Clinical Trial.
European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care.
Cardoso F, McCartney A, Ponti A, Marotti L, Vrieling C, Eniu A, Sousa B, Ripamonti C, Travado L, Spitz S, Jolly E, Curigliano G, Penault-Llorca F, Lecouvet F, Rubio IT, Biganzoli L. Cardoso F, et al. Among authors: vrieling c. Eur J Cancer. 2023 Jul;187:105-113. doi: 10.1016/j.ejca.2023.03.028. Epub 2023 Mar 31. Eur J Cancer. 2023. PMID: 37146504
Cardiovascular disease after cancer therapy.
Aleman BM, Moser EC, Nuver J, Suter TM, Maraldo MV, Specht L, Vrieling C, Darby SC. Aleman BM, et al. Among authors: vrieling c. EJC Suppl. 2014 Jun;12(1):18-28. doi: 10.1016/j.ejcsup.2014.03.002. Epub 2014 May 29. EJC Suppl. 2014. PMID: 26217163 Free PMC article.
The value of 3D images in the aesthetic evaluation of breast cancer conservative treatment. Results from a prospective multicentric clinical trial.
Cardoso MJ, Vrieling C, Cardoso JS, Oliveira HP, Williams NR, Dixon JM; PICTURE Project Clinical Trial Team; PICTURE Project Delphi Panel. Cardoso MJ, et al. Among authors: vrieling c. Breast. 2018 Oct;41:19-24. doi: 10.1016/j.breast.2018.06.008. Epub 2018 Jun 18. Breast. 2018. PMID: 29940498 Clinical Trial.
24 results